AMRI launches a new line in its Valladolid factory05 June 2018
It represents an investment of 5.8 million euros, in addition to 1.4 million euros of public support
The multinational pharmaceutical company Albany Molecular Research Incorporation (AMRI) has launched a new aseptic production line in its plant in the Boecillo Technology Park in Valladolid. With this move, the company, which for over 25 years has been engaged in the research, development and manufacture of pharmaceutical products, improves the production capacity of its factory for the production of sterile products such as syringes. At the same time, it supplements its plants in Bon Encontre and Tonneins, France.
Along with the new production line, AMRI has built an analytical services area and a new warehouse in the facilities to provide additional capacity, technology and experience to respond to the growing demand for its products.
Michael J. Mulhern, chief executive officer of AMRI, says: “We continue to see an increase in interest in our sterile capabilities and are ready to support the growing demand. By adding critical analytical services, we are well positioned to help customers accelerate the pace of their product development while ensuring their performance and quality”.
Production for third parties
AMRI's production lines are equipped to produce everything from a pilot scale to the manufacture of multiple tons, and its sterilization capacity can either be integrated in production or be used to provide this service on a one-off basis to customers who do not have sterile facilities or who may require this capacity.
Mulhern noted the support of the local authorities: “We would like to thank the government of Castile-León for its generosity and continued support. There is a talented scientific and engineering workforce in the region and we are happy to reaffirm our commitment to the region and the expansion of our capabilities and expertise to customers in Europe”.
The government of Castile-León values the investment by the US multinational at 5.8 million euros, to which is added 1.4 million euros of public funding.